Recently, we and others demonstrated that NAMPT is one of the main players in driving BRAFi resistance and melanoma plasticity, mediating metabolic adaptation, reshuffling of the epigenetic landscape and forcing an invasive/mesenchymal/stemness phenotype [8, 9, 11]. The gene discussed is NAMPT; the disease is melanoma.